Financials data is unavailable for this security.
View more
Year on year Dawnrays Pharmaceutical (Holdings) Ltd 's revenues fell -9.90% from 1.28bn to 1.15bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 358.06m to 326.00m, a -8.95% decrease.
Gross margin | 56.58% |
---|---|
Net profit margin | 51.92% |
Operating margin | 62.23% |
Return on assets | 14.74% |
---|---|
Return on equity | 18.54% |
Return on investment | 17.79% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Dawnrays Pharmaceutical (Holdings) Ltd fell by 44.86m. However, the company earned 338.40m from its operations for a Cash Flow Margin of 29.40%. In addition the company generated 2.07m cash from financing while 387.57m was spent on investing.
Cash flow per share | 0.4668 |
---|---|
Price/Cash flow per share | 2.38 |
Book value per share | 2.40 |
---|---|
Tangible book value per share | 2.00 |
More ▼
Balance sheet in CNYView more
Current ratio | 3.40 |
---|---|
Quick ratio | 3.04 |
Total debt/total equity | 0.0576 |
---|---|
Total debt/total capital | 0.0544 |
More ▼
Growth rates in CNY
SmartText is unavailable
Div yield(5 year avg) | 5.54% |
---|---|
Div growth rate (5 year) | 2.00% |
Payout ratio (TTM) | 19.59% |
EPS growth(5 years) | 2.52 |
---|---|
EPS (TTM) vs TTM 1 year ago | 27.38 |
More ▼